PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders
Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration
First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases
Prana Biotechnology is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases.
Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"